



HEALTH ECONOMICS AND OUTCOMES RESEARCH

FELLOWSHIP PROGRAM

UNIVERSITY OF WASHINGTON

2023-2025

ABOUT ABBVIE

- At AbbVie, we strive to make a remarkable impact on the lives of patients. Our focus is clear – we are here to serve patients and we are committed to doing right by them.
- We are a global, research-based biopharmaceutical company committed to discovering, developing and delivering innovative new medicines with distinct and compelling benefits for people.
- We are a passionate, diverse and inclusive organization with a culture that supports the best ideas, wherever they originate.

abbvie

AbbVie Therapeutic Areas

**Allergan
Aesthetics**

Immunology

Oncology
Treating
~60
conditions

Neuroscience
across
30+
brands

Eye Care
in more than
175+
countries

Virology

Women's
Health

Other specialty
• General
medicine

We bring people together because we know that collaboration is the key to breaking barriers and exploring new frontiers in science. We take smart risks that lead to transformative breakthroughs and can change lives for people all over the globe.

Our commitment to making a remarkable impact doesn't end at developing medicines; it begins there. We provide broad support to our patients and help address the health needs of underserved communities. We strive to protect our environment and to make a positive impact in the areas where we live and work.

Health Economics and Outcomes Research (HEOR)

Informing strategic decisions

Ensuring that patients can access and benefit from appropriate therapies in a timely manner

Leveraging innovative research approaches and partnerships

Maximizing the use of real-world evidence and patient-centric outcomes research

**AbbVie
HEOR**

Developing and guiding pricing & reimbursement strategies

Based on the evaluation of the public health policy & reimbursement environment and scientific evaluation of clinical, economic, and patient-centered outcomes data

Forming external expert and payer partnerships

Informing internal and external decisions that positively impact patient lives

Enhancing the patient voice

Leveraging patient self-reported/digital health driven outcomes in clinical trial and real-world settings to further understand the unmet needs and establish value of innovative treatments

1

Product value proposition

...outcomes research strategy based on product value, stakeholder needs & insights

2

Evidence generation and tool development

...through clinical and health economics & outcomes research (HEOR) data

3

Value communication


...about evidence informing the value proposition to stakeholders
...informs health care decision making

ABOUT THE UNIVERSITY OF WASHINGTON

The University of Washington is a world-class leader in health sciences education and has been consistently listed in US News and World Report as one of the top 10 institutions for its graduate programs. The University is particularly noted for its strong research programs and since 1974 has received more federal funds for research and training than any other public university in the United States. It fosters a highly collegial atmosphere between departments and academic units, creating a particularly attractive environment for such partnerships between the public and private sectors.

The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute is housed within the University of Washington School of Pharmacy, which boasts nearly 125 years of academic and research success. Faculty in the program (1) provide advanced research training for graduate students, postdoctoral fellows and clinicians (PharmDs, MDs), (2) conduct rigorous scientific research in economic evaluations and outcomes of pharmaceuticals and other health technologies, and (3) translate and disseminate the results of research into clinical practice and healthcare policy, with the goal of improving patient care.

The CHOICE Institute faculty participating in the fellowship have been chosen both for their dedication to teaching and their excellence in research. Each is trained either as a health economist or health services researcher and all have an extensive history of effective economic evaluations and pharmacoepidemiologic research.



ABOUT OUR FELLOWSHIP

The University of Washington/AbbVie HEOR Fellowship is a two-year program that provides training and hands-on experience in a broad-range of health economics and outcomes research topics. The program is structured to allow fellows to gain proficiency in health outcomes strategy and research as conducted in both academic and pharmaceutical industry settings.

Fellowship Directors



Beth Devine

University of Washington

PharmD, MBA, PhD, FASHP, Professor, Director of Graduate Programs, The Comparative Health Outcomes, Policy, and Economics (CHOICE) Institute

E-Mail: bdevine@uw.edu



Amy Tung

AbbVie

PharmD, MS Director, HEOR Strategy

E-Mail: amy.tung@abbvie.com



Jae Lee

AbbVie

PharmD, MS Senior Manager, HEOR Strategy

E-Mail: jaehyun.lee@abbvie.com

The Fellowship Program

The University of Washington and AbbVie are pleased to offer two, 2-year HEOR Fellowship positions for the academic year 2023-2025. Fellows will spend their first year at the University of Washington (Seattle, WA), and the second year at AbbVie (Irvine, CA; Madison, NJ; or North Chicago, IL). The objective of the first year is to educate fellows on the principles and methods used in health economics and outcomes research. During the second year, fellows are provided with opportunities to gain practical knowledge and experience with the use of clinical, economic, and humanistic data by supporting the development and commercialization of pharmaceutical products. This will be accomplished by participating in work activities undertaken by the HEOR team.

Compensation includes a competitive stipend, basic medical insurance, conference attendance, relocation from Seattle to Irvine, and holiday/vacation time. A Master's (MS) Degree is awarded upon completion of all course requirements and thesis project.



FELLOWSHIP STRUCTURE

First year objectives

The objective of the first year is to provide the fellow with the research tools necessary for economic evaluation and policy assessment. The fellow will be given an overview of pharmaceutical economics and general health policy, and taught methods of economic assessment, health services research, epidemiology, clinical research design, and biostatistical analyses.

The fellow will be assigned a MS thesis project which is selected based on input from both AbbVie as well as the University of Washington mentors. Fellows are highly encouraged to complete their MS project during their first year. Additionally, fellows will also engage in ongoing projects with AbbVie throughout their first year, applying skills from previous pharmacy training as well as integrating new techniques developed from University of Washington courses. Applying learning to solve real-world problems is a constant focus of the fellowship.

The fellow's actual course of study will be developed on an individual basis with the Program Director, Dr. Beth Devine, but will consist of courses in biostatistics, epidemiology, economic evaluations and outcomes research, and health and pharmaceutical policy.

After completion of the first year, the fellow will have a clear understanding of:

General principles of economics and in particular how economics influences the use, cost, and availability of pharmaceuticals.

The complex structure of drug policy and how it determines relationships between consumers, health care providers, insurers, payers, and government agencies.

The breadth and scope of analytical methods needed for the assessment of Patient Reported Outcomes (PROs), economic modeling, retrospective database studies, and observational studies.

Formulary development, maintenance and evaluation in institutional, managed care, and state-level government programs.

Second year objectives

The second year of training will be at AbbVie with the HEOR department. This part of the program is designed to allow the fellow to learn about the role of economic evaluations and outcomes research in the drug development and commercialization process within the industry setting. The research may be on an existing or experimental product for a disease state that is of interest to AbbVie.

In addition to completing individual research project(s), fellows will participate in ongoing economic evaluations, outcomes research, and other projects in collaboration with the HEOR team.

These experiences will provide the fellow with opportunities to interact with team members in other departments at AbbVie to learn how economic analyses and outcomes research are used throughout the pharmaceutical industry. Fellows will see firsthand how outcomes research is utilized to demonstrate the place of AbbVie products in treatment pathways and its value.

PERSPECTIVES FROM PAST AND CURRENT FELLOWS

Insights from current AbbVie colleagues



(2014-2016)

Katelyn Keyloun



The fellowship experience was didactic and robust in learning the skills necessary to conduct pharmacoeconomics and health outcomes research as well as to lead strategy for a pharmaceutical company.”



(2018-2022)

Jamie Ta



The MS program at CHOICE, together with the multiple opportunities I had to lead high-impact HEOR studies, collaborate with cross-functional partners, and support HEOR strategy... helped me gain a better understanding of the role of HEOR in the pharmaceutical industry and develop the technical, leadership, and communication skills that have prepared me well for my current role.”



(2019-2021)

Jae Lee



The goal of our program is to equip our fellows with the training and skills necessary to succeed in HEOR. Over half our past fellows have stayed on with the company following their fellowship and this speaks to the quality of our program and our fellows.”



(2020-2022)

Kim Cai



My most memorable experience was applying my research skills from my thesis work to our protocol designs for real-world studies on QULIPTA (Atogepant) and seeing the direct transferability of those skills. Seeing my research impact business use helped me understand my role in bringing forth patient access to new therapies.”



(2020-2022)

TJ Park



Completing the UW/AbbVie HEOR fellowship was a very rewarding experience. The academic and industry mentors are all incredibly supportive and the cross-company fellow cohort brings a sense of community.”



(2021-2023)

Gina Ahmadyar



The most memorable experience for me was the moment I completed the analysis for my thesis. It was an incredible feeling to take it from an idea and culminate it into tangible results.”



(2021-2023)

Annaliza Dominguez



Being able to apply the knowledge and technical skillset gained during my first year have helped me tremendously in being able to manage a variety of projects in my second year, including leading studies in RWE and PROs on both the pharma and device side.”



(2022-2024)

Jae Kim



The conversational nature of the interview process stood out to me, and I got a great sense of how willing AbbVie was in helping their fellows develop.”



(2022-2024)

Zach Baldwin



Throughout the interview process I felt that the people in the meeting were truthfully listening to my responses and were exploring what I had said to answer their original questions. It didn't seem as if there was a list of questions they had to get through before the end of the interview and it all felt very natural.”

CURRENT FELLOWS



First Year Fellows


ZACHARY BALDWIN,
PharmD



ZACH is a first year Postdoctoral Fellow with the UW CHOICE Institute and AbbVie. He received his PharmD from the University of Washington. Zach developed an interest in HEOR during his first year in AMCP's P&T competition. During his time in pharmacy school, Zach has supported projects with NHLBI on sickle cell disease as well as ICER on chemotherapy-induced myelosuppression in lung and breast cancers. He also assisted the NIH-funded Clinical Sequencing Evidence-Generating Research Consortium on their work evaluating CEA frameworks for genome and exome sequencing compared to traditional diagnostic pathways.

ZACH is excited to further expand his understanding of HEOR by learning from the renowned thought-leaders that UW and AbbVie have to offer. He looks forward to the ideal learning environment that has been created with the CHOICE/AbbVie partnership: a combination of real-world industry exposure and hands-on technical practice. Zach's thesis will be utilizing real-world data to explore issues in Parkinson's Disease, a disease state he's incredibly passionate about.

JAE KIM,
PharmD



JAE is a first-year UW/AbbVie HEOR Postdoctoral Fellow. He earned his PharmD from the University of Michigan. During pharmacy school, Jae was able to work in multiple functional areas and with formulary decision-makers. He developed an interest in HEOR through these experiences as he realized the utility of real-world evidence and the importance of developing strong value propositions for treatment options. He also has past experiences in industry, research, managed care, and consulting.


JAE is excited about the opportunity to work with the UW CHOICE faculty and AbbVie team to build upon his current skillset. He is looking forward to developing a strong foundation in HEOR through the combination of training at UW and practical industry experience at AbbVie. For his thesis, he will be examining health care resource utilization and associated costs with a delayed migraine diagnosis.

CURRENT FELLOWS



Second Year Fellows

GINA AHMADYAR,
PharmD, MS



GINA earned her PharmD from the University of California, San Francisco (UCSF) School of Pharmacy. During the first year of fellowship, Gina worked under the mentorship of Drs. Ryan Hansen, Josh Carlson, Joanna Campbell, and Vanessa Shih to assess the treatment patterns and economic burden of post-cataract macular edema.

Now in her second year, she is continuing her work with AbbVie's eye care team with Ali Alobaidi. Gina is excited to apply what she has learned during the first year of fellowship to her current work and to continue developing her skillsets in health economics and outcomes research.

ABSTRACTS FROM FELLOWSHIP:

- Ahmadyar G, Hansen R. Ocular Injectable Treatment Options for Post-Cataract Macular Edema: A Systematic Review. UW Corporate Advisory Board Meeting, September 2021, Seattle, WA. (Online Poster)

MANUSCRIPTS FROM FELLOWSHIP:

- Ahmadyar G, Hansen R. Ocular Injectable Treatment Options for Post-Cataract Macular Edema: A Systematic Review of Current Literature. J Cataract Refract Surg. 2022 Feb 10. doi: 10.1097/j.jcrs.0000000000000908. Epub ahead of print. PMID: 35171142.
- Ahmadyar G, Hansen R, Carlson J, Alobaidi A, Hallak J. Treatment Patterns and Economic Burden of Post-Cataract Macular Edema. (In Progress).

ANNALIZA DOMINGUEZ,
PharmD, MS



ANNALIZA earned her PharmD from the University of Southern California (USC) School of Pharmacy, where she also completed a master's degree in healthcare decision analysis. During her first year of the fellowship, Annaliza worked with Drs. Josh Carlson, Ryan Hansen, Julie Garcia, and Vaishali Patel to evaluate the effect of treatment satisfaction on future spending for professional cosmetic treatments among aesthetically conscious U.S. adults.

In her second year, Annaliza continues to work in AbbVie's Patient Centered Outcomes Research (PCOR) team with Julie Garcia in aesthetics. Annaliza looks forward to continuing her training in HEOR as she applies her current knowledge and skillset to various projects within AbbVie.

ABSTRACTS FROM FELLOWSHIP:

- Dominguez A, Carlson JJ. Measuring Satisfaction & Psychosocial Impact for Non-Invasive Facial Cosmetic Treatments: A Systematic Review. UW Corporate Advisory Board Meeting, September 2021, Seattle, WA. (Online Poster)

MANUSCRIPTS FROM FELLOWSHIP:

- Dominguez A, Carlson JJ, Garcia J, Patel V. Evaluating Treatment Satisfaction on Future Spending for Professional Cosmetic Treatments Among Aesthetically Conscious U.S. Adults. (In Progress)

PAST FELLOWS

TAE JIN PARK

PharmD, MS 2020-2022

Senior Manager, Health Economics and Outcomes Research
AbbVie, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Park T, Higa S, Gillard P, Hansen R, Devine B. Evaluating Healthcare Resource Utilization and Associated Costs in Patients with New-Onset Postoperative Atrial Fibrillation. (In Progress)

KIM CAI

PharmD, MS 2020-2022

Manager, Health Economics and Outcomes Research
AbbVie, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Cai K, Gandhi P, Burslem K, Barker-Haliski M, Devine B. Evaluating Healthcare Resource Use and Associated Costs in Patients with Chronic or Episodic Migraine. (In Progress)

BRENNAN BEAL

PharmD, MS 2019-2021

Quantitative Scientist
Flatiron Health, New York, NY

KEY RESEARCH FROM FELLOWSHIP

1. Beal B, Shih V, Campbell J, Veenstra D, Devine B. Comparing healthcare resource utilization and costs for patients with normal tension glaucoma across levels of severity: a retrospective cohort study. *Clin Ophthalmol.* 2021;15:453–60.
2. Chen S, Graff J, Yun S, Beal B, Ta JT, Bansal A, et al. Online tools to synthesize real-world evidence of comparative effectiveness research to enhance formulary decision making. *J Manag Care Spec Pharm.* 2021 Jan;27(1):95–104.

JAE HYUN LEE

PharmD, MS 2019-2021

Senior Manager, Health Economics and Outcomes Research
AbbVie, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Lee J, Shewale A, Barthold D, Devine B. Geographic Variation in the Use of Triptans and Opioids for the Acute Treatment of Migraine Attacks. *Headache: The Journal of Head and Face Pain.* 2021 Nov;61(10):1499-1510.

ASHLEY KIM

PharmD, MS 2018-2020

Senior Manager, Health Economics and Outcomes Research
GRAIL, Inc., Menlo Park, CA

KEY RESEARCH FROM FELLOWSHIP

1. Kim A, Devine B, Campbell J, Shirneshan E, Zhao C, Bansal A. Healthcare resource utilization and costs in patients with geographic atrophy secondary to age-related macular degeneration. *Clin Ophthalmol.* 2021;15:2643–51.
2. Kim A, Devine B, Roth JA. Cost-effectiveness of first-line pembrolizumab plus chemotherapy for metastatic squamous non-small cell lung cancer (Nsccl). *JCO.* 2019 May 20;37(15_suppl):e20703–e20703.

JAMIE TA

PharmD, MS 2018-2020

Associate Director, Health Economics and Outcomes Research
AbbVie, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Ta JT, Sullivan SD, Tung A, Oliveri D, Gillard P, Devine B. Health care resource utilization and costs associated with nonadherence and nonpersistence to antidepressants in major depressive disorder. *J Manag Care Spec Pharm.* 2021 Feb;27(2):223–39.

SARA HIGA

PharmD, MS 2017-2019

Senior Manager, Health Economics and Outcomes Research
Agiros Pharmaceuticals, Cambridge, MA

KEY RESEARCH FROM FELLOWSHIP

1. Higa S, Devine B, Patel V, Baradaran S, Wang D, Bansal A. Psoriasis treatment patterns: a retrospective claims study. *Curr Med Res Opin.* 2019 Jun 17:1-7

CHIEMEKA IKE

MPH, PharmD, MS 2017-2019

Associate Director, Health Economics and Outcomes
EMD Serono, Inc., Rockland, MA

KEY RESEARCH FROM FELLOWSHIP

1. Ike C, Marcum Z, Shewale A, Viswanathan H, Cotton S, Johnson C, Jackson J, Devine B. Treatment Patterns, Discontinuation and Switching of Acute Medications for Migraine: A Cross-Sectional Survey of Real-World Evidence from a Multi-Country Perspective. (In Progress)

MICHAEL SERBIN

PharmD, MS 2016-2018

Director, Health Economics and Outcomes Research
Neurocrine Biosciences, San Diego, CA

KEY RESEARCH FROM FELLOWSHIP

1. Serbin M, Devine B, Campbell J, Basu A. Assessing health care burden in glaucoma patients with and without physical or mental comorbidities. *J Manag Care Spec Pharm.* 2020 Mar;26(3):325–31.

SHEILA SHAPOURI

PharmD, MS 2016-2018

Health Economist, Evidence for Access (BioOncology)
Genentech, Inc., South San Francisco, CA

KEY RESEARCH FROM FELLOWSHIP

1. Shapouri S, Devine EB, Keyloun KR, Gillard PJ, Sabbatini AK, Bansal A. Predicting Hospitalizations and Returns to the Emergency Department 30-Days Post Emergency Department Discharge Among Patients with Acute Bacterial Skin and Skin Structure Infections.

SARAH BARADARAN

PharmD, MS 2015-2017

Director, Health Economics and Outcomes Research
Sage Therapeutics, Cambridge, MA

KEY RESEARCH FROM FELLOWSHIP

1. Baradaran S, Black D, Keyloun K, Hansen R, Gillard P, Devine B; The Impact of Acute Kidney Injury on the Risk of Mortality and Health Care Utilization Among Patients Treated With Polymyxins for Severe Gram-Negative Infections, *Open Forum Infectious Diseases*, Volume 5, Issue 8, 1 August 2018.
2. Kagan R, Martin A, Sarri G, Guo Y, Baradaran S, Harrington A. The Burden of Illness Associated with Symptomatic Vulvovaginal Atrophy (VVA): A Systematic Review. (In Progress)
3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. *AMIA Joint Summits on Translational Science proceedings. AMIA Joint Summits on Translational Science.* 2017; 2017:30-39.

AMY TUNG

PharmD, MS 2015-2017

Director, Health Economics and Outcomes Research
AbbVie, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Tung A, Hepp Z, Bansal A, Devine EB. Characterizing Health Care Utilization, Direct Costs, and Comorbidities Associated with Interstitial Cystitis: A Retrospective Claims Analysis. *J Manag Care Spec Pharm.* 2017 Apr;23(4):474-482.
2. Dmochowski R, Brucker BM, Cole E, Kawahara S, Pulicharam R, Burk C, Tung A, Hale D. Economic Burden of Illness in Adult Patients with Nocturia. *J Manag Care Spec Pharm.* 2019 May;25(5):593-604.

PAST FELLOWS

KAELYN KEYLOUN

PharmD, MS 2014-2016

Associate Director, Health Economics and Outcomes Research
AbbVie, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Keyloun KR, Hansen R, Hepp Z, Gillard P, Thase M, Devine EB. Adherence and Persistence Across Antidepressant Therapeutic Class: A Retrospective Claims Analysis Among Insured U S Patients with Major Depressive Disorder (MDD). *C N S Drugs*. 2017 May;31(5):421-432.
2. Mathias P, Hendrix N, Wang W, Keyloun KR, Khelifi M, Tarczy-Hornoch P, Devine EB. Characterizing pharmacogenomic-guided medication use with a clinical data repository. *Clin Pharmacol Ther*. 2017 Aug;102(2):340-348.
3. Chin L, Devine B, Baradaran S, Keyloun K, Canestaro W, Pham J. Characterizing the Strength of Evidence in FDA Labels for Pharmacogenomic Biomarker-Guided Medication Use. *AMIA Joint Summits on Translational Science*. 2017 Jul; eCollection.

VANESSA SHIH

PharmD, MS 2014-2016

Director, Health Economics and Outcomes Research
Seattle Genetics, Seattle, WA

KEY RESEARCH FROM FELLOWSHIP

1. Shih V, Campbell J, Devine EB. The Association between Onset of Vision Impairment and Functional Limitations and Informal Caregiving Requirements in Older Americans.

TRACY YEP

PharmD, MS 2013-2015

Utilization Management and Specialty Coordinator
Kaiser Permanente of Washington, Seattle, WA

KEY RESEARCH FROM FELLOWSHIP

1. Yep T, Patel VD, Slejko JF, Devine EB. Comparing Total and Disease Related Healthcare Cost for Glaucoma Patients by Disease Severity: A Retrospective Claims Database Analysis. (In Progress)

ZSOLT HEPP

PharmD, MS 2012-2014

Senior Director, Global Health Economics and Outcomes Research, Seattle Genetics, Seattle, WA

KEY RESEARCH FROM FELLOWSHIP

1. Hepp Z, David DW, Gillard P, Varon SF, Hansen RN, Devine EB. Adherence to oral migraine-preventive medications among patients with chronic migraine. *Cephalalgia*. 2015 May;35(6):478-88.
2. Forrester S, Hepp Z, Roth J, Wirtz H, Devine EB. Cost-effectiveness of a computerized provider order entry system in improving medication safety in ambulatory care. *Value Health*. 2014 Jun;17(4):340-9
3. Hepp Z, Dodick DW, Varon SF, Chia J, Matthew N, Gillard P, Hansen RN, Devine EB. Persistence and switching patterns of oral migraine prophylactic medications among patients with chronic migraine: A retrospective claims analysis. *Cephalalgia*. 2017 Apr;37(5):470-485.

CHRIS WALLICK

MPH, PharmD, MS 2012-2014

Principal Health Economist
Genentech, Inc., South San Francisco, CA

KEY RESEARCH FROM FELLOWSHIP

1. Stewart Williams JA, Wallick CJ, Byles JE, Doran CM. Assessing patterns of use of cardio-protective poly-pill component medicines in Australian women. *Drugs Aging* (2013)30:193-203
2. Wallick CJ, Hansen RN, Campbell J, Kiss S, Kowalski JW, Sullivan SD. Comorbidity and Health Care Resource Use Among Commercially Insured Non-Elderly Patients With Diabetic Macular Edema. *Ophthalmic surgery, lasers & imaging retina*. 2015 Jul-Aug;46(7):744-51
3. Wallick CJ, Sullivan SD, Hansen RN, Campbell JH, Kowalski JW. The Cost of Diabetic Macular Edema in a Commercially Insured

VINCENT W.LIN

PharmD, MS 2010-2012

Senior Director, Health Economics and Real World Evidence
Autolus Ltd, London, United Kingdom

KEY RESEARCH FROM FELLOWSHIP

1. Lin VW, Ringold S, Devine BE. Comparison of Ustekinumab with other Biologic Agents for Treatment of Moderate-to-Severe Psoriasis: A Bayesian Network Meta-Analysis. *Arch Dermatol*. 2012 Dec;148(12):1403-10
2. Lin VW, Wright A, Flum DR, Alfonso RA, Garrison LP, Sullivan SD. Patients' experience and outcomes after laparoscopic adjustable gastric banding in Washington State. *Surg Obes Relat Dis*. 2013 Sep- Oct;9(5):701-5
3. Lin VW, Wong ES, Wright A. Association between health-related quality of life and body mass after adjustable gastric banding: a nonlinear approach. *Value in Health*. 2013 Jul;16(5):823-9

PATRICK GILLARD

PharmD, MS 2009-2010

Executive Director, Health Economics and Outcomes Research
AbbVie, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Gillard PJ, Devine B, Varon SF, Liu L, Sullivan SD. Mapping from Disease-Specific Measures to Health-State Utility Values in Individuals with Migraine. *Value in Health* 2012;15(3):485-94.
2. Doan QV, Brashear A, Gillard PJ, Varon SF, Turkel CC, Vandenburg AM, Elovic EP. Relationship Between Disability Due to Upper-Limb Post-Stroke Spasticity and Health-Related Quality of Life and Caregiver Burden. *PM&R* 2012;4(1):4-10.

KATHARINE S. GRIES

PharmD, MS, PHD 2008-2010

Director, Patient Reported Outcomes
The Janssen Pharmaceutical Companies of Johnson & Johnson, Raritan, NJ

KEY RESEARCH FROM FELLOWSHIP

1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Successes for Overactive Bladder with Urinary Urge Incontinence Refractory to Oral Antimuscarinics: A Review of Published Evidence. *BMC Urology*, 2009; 9(18)

JONATHAN H. WATANABE

PharmD, PhD 2007-2009

Professor of Clinical Pharmacy, Associate Dean of Assessment and Quality
UCI, Irvine, CA

KEY RESEARCH FROM FELLOWSHIP

1. Campbell JD, Gries KS, Watanabe JH, Ravelo A, Dmochowski RR, Sullivan SD. Treatment Success for Overactive Bladder with Urinary Urge Incontinence Refractory Oral Antimuscarinics. *BMC Urology*, 2009 Nov;20;9(18).
2. Watanabe JH, Campbell JD, Ravelo A, Chancellor MB, Kowalski J, Sullivan SD. Cost Analysis of Interventions for Antimuscarinic Refractory Patients with Overactive Bladder. *Urology*, 2010 Oct;76(4):835-40.
3. Sand P, Rovner E, Dmochowski R, Watanabe JH, Oefelein MG. Once-daily Trosipium Chloride 60 mg Extended Release is Safe and Effective in Subjects with the Overactive Bladder Syndrome who Use Multiple Concomitant Medications. *Drugs Aging*, 2011 Feb;1;28(2):151-60
4. Patel VD, Watanabe JH, Strauss JA, Dubey AT. Work productivity loss in patients with dry eye disease: an online survey. *Curr Med Res Opin*, 2011 May, 27(5):1041-8.

APPLICATION ELIGIBILITY

Applicants for this fellowship must have a degree in pharmacy and have some research experience (preference will be given to those with a high academic standing). Excellent written and verbal communication skills are also essential. Applicants will be required to submit their curriculum vitae, a letter describing their career goals, and three letters of recommendation.

Selection of fellows will be made by a steering committee composed of the University of Washington faculty members and representatives from AbbVie.



DEADLINE
October 28, 2022

APPLICATION INFORMATION

Interested students must apply to the University of Washington Graduate School Online Interview. The online application process can be found at: <https://sop.washington.edu/choice/graduate-education-trainingprograms/ms-heor-fellowships/>

Fellowship Information Session

September 26, 2022

5:00 PM - 6:00 PM Pacific Time

Registration required: <https://bit.ly/UW-HEOR-2022> [bit.ly]

ABBVIE FELLOWSHIP PROGRAMS

University Location	Seattle, WA
AbbVie Location	Irvine, CA; Madison, NJ; or North Chicago, IL
Program Length	2 years
Programs Offered	Health Economics and Outcomes Research
Eligibility	Degree in Pharmacy

CONTACT INFORMATION

If you have any questions, please contact:

University of Washington

Marina Gano, M.Ed

Graduate Program & Operations Manager

1959 N E Pacific St. Suite H375,

Box 357630 Seattle, WA 98195

E-Mail: mcgano@uw.edu

Phone: 206- 616-1383

AbbVie

Jae Lee, PharmD, MS

Senior Manager, HEOR Strategy

2525 Dupont Drive

Irvine, CA 92612

Email: jaehyun.lee@abbvie.com

Phone: 714-246-2593